GRI Bio (GRI), a biotechnology company, on Tuesday reported interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for Idiopathic Pulmonary Fibrosis or IPF.
The study demonstrated that GRI-0621 (4.5mg, taken orally once daily) was safe and well-tolerated in the first 12 patients evaluated. No significant changes were observed in LDL, HDL, triglyceride, or total cholesterol (TG) levels, as assessed at the 2-week visit.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com